Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Reinnervate Ltd and Roslin Cellab Partner

Published: Friday, September 20, 2013
Last Updated: Friday, September 20, 2013
Bookmark and Share
Reinnervate Ltd announced that it is entering into a collaboration with Roslin Cellab to develop 3D stem cell printing products and services using Alvetex® technology.

The two companies will pool their expertise in the areas of 3D cell culture and stem cell biology to bring next generation stem cell products and services to the market. Reinnervate will contribute new Alvetex 3D cell culture variants and expertise while Roslin Cellab will harness its capabilities in the area of stem cell culture and cell printing.

„We are delighted to deepen our links with Reinnervate by working together in this area‟ commented Dr. Jason King, Business Development Manager at Roslin Cellab. „This work builds on our earlier collaboration on the 3D culture and differentiation of stem cells using Alvetex‟ he added.

Richard Rowling, Commercial Director of Reinnervate Ltd said, „We are very pleased that Roslin Cellab has once again picked Alvetex technology as one of the most appropriate and flexible solutions for 3D cell culture for this new venture. The simple workflow and flexibility of Alvetex products make them an excellent companion for 3D cell printing projects‟


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Reinnervate Partners with Oncotest and SBH Sciences
Companies to partner on introductory services for screening novel anti-cancer drugs using 3D tumour cell culture.
Thursday, October 31, 2013
3D cell Culture Firm Reinnervate and Specialist Oncology CRO Oncotest GmbH Enter Collaboration Agreement
Oncotest to offer enhanced pre-clinical oncology and cancer research screening services incorporating Alvetex®Scaffold 3D cell culture technology.
Monday, January 07, 2013
Reinnervate and Tecan Sign Co-marketing Agreement
Both Companies to develop automated 3D cell culture solutions for improved cellular assays.
Tuesday, November 27, 2012
Reinnervate and Roslin Cellab Announce Plans to Collaborate
Collaboration on the development of protocols for three dimensional growth of hESC’s using Alvetex®Scaffold.
Friday, April 27, 2012
Reinnervate and Kirkstall to Collaborate on New 3D Cell Culture Products
Companies will collaborate to bring next generation three dimensional (3D) cell culture products to market in 2012. The two UK companies develop cell culture systems that bridge the current gap between 2D in-vitro cell culture and animal models.
Monday, March 19, 2012
New Reinnervate Whitepaper Includes Details on Live 3D Cell Imaging in 3D Cell Culture Using Alvetex®
The release is set to help scientists make the switch from traditional 2D cell culture to 3D cell growth.
Monday, January 30, 2012
Reinnervate and Mirus Bio announce collaboration
Reinnervate and Mirus Bio announce commercial agreement to launch new range of products for the transfection of cells cultured in 3D.
Friday, November 18, 2011
Alvetex® Voted One of Most Technologically Significant New Research Products By R&D Magazine
Alvetex® enables genuine 3D cell growth to be performed routinely and cost effectively in cell biology laboratories.
Monday, June 27, 2011
Reinnervate Partners with AMS Biotechnology (Europe) Limited for Distribution of Alvetex®
Alvetex® is a unique and proprietary cell culture scaffold that enables genuine 3D cell growth to be performed routinely and cost-effectively in cell biology laboratories.
Wednesday, June 01, 2011
Reinnervate Enhances Commercial and Product Development Teams with Key Senior Appointments
Appointments of Richard Rowling as commercial director and Barry Lynch as marketing manager to lead the sales and marketing operations supporting alvetex®.
Wednesday, April 06, 2011
Alvetex® Named in the “Top Ten Life Science Innovations of 2010” by The Scientist Magazine
Reinnervate’s 3D cell culture technology selected as one the ten most exciting new tools to hit the life sciences market this year.
Monday, December 06, 2010
Reinnervate Partners with LGC for Global Distribution of Alvetex®
Additional collaboration to develop 3d cell cultures for applications in drug discovery and development.
Tuesday, November 30, 2010
Reinnervate Partners with LGC for Global Distribution of ALVETEX®
Additional collaboration to develop 3D cell cultures for applications in drug discovery and development.
Monday, November 29, 2010
Reinnervate Completes Expansion into New Purpose-Built Facility at Netpark
Reinnervate, a life sciences company driving the adoption of routine 3D cell culture, has announced its expansion into a new purpose-built research and production facility at NETPark near Sedgefield, UK.
Tuesday, November 16, 2010
Reinnervate Launches new Website with Interactive Technical Resource for Routine 3D Cell Culture
New site provides scientific and technical information on 3D cell culture based on Reinnervate’s core Alvetex® technology.
Wednesday, October 13, 2010
Scientific News
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Bioreactors Ready for the Big Time
Bioreactors are passive filtration systems that can reduce nitrate losses from farm fields.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
‘Mini-Brains’ to Study Zika
Novel tool expected to speed research on brain and drug development.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!